Department of Biomedical Engineering - Distinguished Lecture Series: "Translational tissue engineering for skeletal muscle repair and regeneration" by George J. Christ, PhD, University of Virginia


BME Distinguished Lecture Event Image alt
BME Distinguished Lecture Event Image
Monday, March 26, 2018
4:00 pm to 5:00 pm
Floor/Room #: 
GP 1002
George J. Christ, PhD
University of Virginia
Professor of Biomedical Engineering and Orthopaedic Surgery
Mary Muilenberg Stamp Professor of Orthopaedic Research
Director of Basic and Translational Research in Orthopaedic Surgery
Co-Director Center for Advanced Biomanufacturing


Dr. Christ is an internationally recognized expert in muscle physiology. He is the Past Chairman of the Division of Systems and Integrative Pharmacology of the American Society of Pharmacology and Experimental Therapeutics (ASPET), and Past President of the North Carolina Tissue Engineering and Regenerative Medicine (NCTERM) group. He was inducted into AIMBE in 2017. He currently serves on the Executive Committee of the Division for Integrative Systems, Translational and Clinical Pharmacology of ASPET. He is also on the Editorial Board of five journals and is an ad-hoc reviewer for 2 dozen others. Dr. Christ has authored more than 220 scientific publications and is co-editor of a book on integrative smooth muscle physiology and another on regenerative pharmacology. Dr. Christ has served on both national and international committees related to his expertise in muscle physiology, and on NIH study sections in the NIDDK, NICHD, NCRR, NAIAD, and NHLBI. He has chaired working groups for both the NIH and the World Health Organization. Dr. Christ is a co-inventor on more than 26 patents (national and international) that are either issued or pending, related to gene therapy for the treatment of human smooth muscle disorders and tissue engineering technologies. Dr. Christ has also been the driving scientific force behind the preclinical studies and IND approvals supporting three Phase I clinical trials for gene therapy for benign human smooth muscle disorders. This technology has been evaluated in 55 patients in the US and 21 overseas. He is also spearheading the multi-institutional development of a tissue engineered muscle repair (

TEMR) technology platform for the treatment of Wounded Warriors. An IND submission for a 5 patient first-in-man pilot study is anticipated in 2018 to further develop this technology platform for treatment of cleft lip. That study is funded by DOD and will be conducted at UT-Houston. Another 5 patient pilot study has also been funded by DOD to evaluate a proprietary hydrogel for the treatment of lower extremity volumetric muscle loss injuries to the tibialis anterior muscle at UVA. An IDE application for that indication is in progress in collaboration with Keranetics LLC (W-S, NC). 

Phone Number: